NEW YORK--( / ) November 20, 2015 -- The Estee Lauder Companies Inc. (NYSE:EL) today announced the following executive appointments, effective January 1, 2016:
· John Demsey will expand his responsibilities and become Executive Group President, The Estee Lauder Companies. Mr. Demsey will add Clinique and the Men’s Skincare Group to his portfolio while continuing to oversee Aramis and Designer Fragrances, Prescriptives, M·A·C Cosmetics (“M·A·C”), Bobbi Brown, Jo Malone London, Bumble and bumble, Tom Ford, Smashbox, RODIN olio lusso, Le Labo, Editions de Parfums Frederic Malle and GLAMGLOW. In his role, Mr. Demsey will also lead a newly created Center of Excellence for Creative, continuing to advance capabilities, processes and talent development in this important area for the Company.
· Jane Hertzmark Hudis will become Group President, The Estee Lauder Companies. Ms. Hudis will continue to lead the Company’s Estee Lauder and AERIN brands while adding La Mer, Darphin, Origins and Aveda to her portfolio. Ms. Hudis will also join several leadership committees within the Company.
Both executives will report directly to Fabrizio Freda, President and Chief Executive Officer. These appointments follow the previously announced retirement of Lynne Greene, Group President, and are part of the Company’s continuous organizational evolution to further align its expanding portfolio of brands while providing key leaders with increased opportunities. Ms. Greene will work closely with Mr. Demsey and Ms. Hudis to help ensure a seamless transition of responsibilities, as Ms. Greene prepares to retire on June 30, 2016.
Mr. Freda said, “These appointments for John and Jane recognize their strong leadership and unparalleled ability to drive the continued future success of our diverse portfolio of prestige brands. They also have a keen understanding of our key strategic initiatives, including Creativity, Innovation, Digital and Emerging Market growth, and have demonstrated relentless commitment and leadership to advancing our business in these areas. I look forward to continuing to work closely with Jane and John on their increased responsibilities.”
Mr. Demsey has served as Group President, The Estee Lauder Companies, since July 2006. After joining the Company in 1991, Mr. Demsey held numerous positions of increasing responsibility, including his appointment in 1998 to President of M·A·C which, under his leadership, grew from a small, niche makeup artist brand to a global cosmetics powerhouse distributed in more than 100 countries/territories worldwide. Mr. Demsey has overseen the continued success and expansion of many brands in the Company’s portfolio, including several of the Company’s fastest growing brands, such as Tom Ford, Jo Malone London and Smashbox. He has also been an integral enterprise leader on many organizational transformation activities, including the Company’s recent acquisitions.
“John is well-known across the industry as a strong business leader and a creative visionary. His extraordinary creative taste makes him an ideal fit to also become be the leader of an enterprise-wide Creative Center of Excellence, helping to drive our renowned competitive advantage in this area through the advancement of Creative capabilities, processes and talent development,” Mr. Freda added.
Ms. Hudis was appointed Global Brand President, Estee Lauder, in July 2009. She has been dedicated to building on Estee Lauder‘s rich heritage to bring the brand to a new generation of global consumers. Under her leadership, the brand’s net sales have grown more than 40 percent. Additionally, Ms. Hudis’ extraordinary insights and knowledge of the Asian consumer helped drive Estee Lauder to be the number one prestige brand in its distribution in Asia. Before assuming her current role, Ms. Hudis served as President of the Company’s Origins brand as well as BeautyBank, a division she founded in 2003 to develop innovative new brand concepts for The Estee Lauder Companies.
Mr. Freda continued, “Jane’s expanded portfolio of brands will strongly benefit from her best-in-class leadership as an excellent brand marketer with a strong commitment to quality. She is also widely recognized for her expertise in local relevance ? tailoring product innovation and marketing to our consumers ? and her excellent ability to grow brand appeal across multiple generations, from ageless consumers to millennials.”
“Throughout his outstanding career, John has overseen the continued success and expansion of many brands in the Company’s portfolio. The new additions to John’s portfolio, Clinique and the Men’s Skincare Group, will benefit from his unique business talent and world-class creativity,” said William P. Lauder, Executive Chairman. “Jane has a longstanding tenure of leading both small and big brands with deep heritage, authenticity, and unique brand positioning. The addition of La Mer, Darphin, Origins and Aveda to her portfolio is a natural fit for Jane to leverage her brand building expertise to further elevate and grow these brands.”
“I had the unique pleasure of bringing both John and Jane into the Company early on in their careers, and I’m proud to see them taking on even more leadership responsibilities. They bring innovation, creativity, style and a distinctly modern approach to our Company?all of which are vital to our business as they lead our brands into the future,” said Leonard A. Lauder, Chairman Emeritus.
About The Estee Lauder Companies Inc.
The Estee Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 150 countries and territories under brand names including: Estee Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Marni, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frederic Malle and GLAMGLOW.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
Boehringer Ingelheim today announced that the Committee 오피야 BoehringerMedicinal Products for Human Use (CHMP) of the European Medicines Agency 야한만화보기 (EMA) has issued a positive 야한만화보기 아스피린 비아그라 opinion for nintedanib* (suggested brand name OFEV®) for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Results from the Phase III INPULSIS® trials, published in the New England Journal of Medicine in May, showed that nintedanib* significantly slowed disease progression in a broad range of patients with IPF**.1 The opinion comes after the recent Food and 토토센터 비닉스 센트립 Drug Administration (FDA) approval of nintedanib* for the treatment of IPF.
“Boehringer Ingelheim welcomes the decision 토토센터 by the CHMP. There has been a high unmet 야한만화보기 네트워크공유설정 need for effective 야한만화보기 네트워크공유방법 treatments that can slow disease progression in IPF. We look forward to making nintedanib available soon to patients with IPF in the 올누드 “Boehringersaid Professor 토토센터 Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim.
IPF is a debilitating 야한카페 IPFfatal lung disease with a 토토센터 당뇨성발기부전 median survival of 2-3 주나일 IPFafter diagnosis.2 It causes progressive scarring of the lungs, 토토센터 기가공유검색어패치 실시간tv시청 IPFin continual and irreversible 야한만화보기 비뇨기과발기 deterioration 야한만화보기 in lung function and difficulty breathing.3 토토센터 기가공유사이트
“This decision is very encouraging as patients with 야한만화보기 줄기세포발기부전 IPF currently have very limited treatment 실시간tv시청 “Thissaid INPULSIS® study investigator Professor Luca Richeldi, Professor of Respiratory Medicine, Chair of Interstitial Lung 야한만화보기 flickr특징 Disease at the University of 실시간tv시청 “ThisUnited Kingdom. “For the 블랙TV “Thistime we have a drug that has consistently met the primary endpoint in two large 야한만화보기 소화제 Phase III trials, confirming the 토토센터 results of the Phase II trial.”
The CHMP’s positive opinion is based on pivotal data from 야한만화보기 the replicate Phase III 토토센터 외국사진사이트 INPULSIS® trials involving 1,066 patients from 24 countries. INPULSIS® results showed that nintedanib* slowed disease progression by reducing the annual 엠스팟 Theof decline in lung function by 50% in a broad range of IPF patient types: this included patients with early disease (forced vital capacity (FVC) >90% pred), limited radiographic fibrosis (no honeycombing) on high resolution computed tomography (HRCT) and those with emphysema.1 야한만화보기 프릴리지정60MG As well, nintedanib* significantly reduced the risk of adjudicated acute 카지노인벤 Theby 68%.1 This can be crucial given that approximately 50% of patients hospitalised for an 토토센터 세토펜 acute IPF exacerbation die during hospitalisation.4
Nintedanib* in IPF has been granted accelerated assessment by the EMA. Nintedanib*, one capsule twice 토토센터 헥사메딘액 a day, 토토센터 키트주사 is the first treatment for IPF that has consistently demonstrated a significant reduction in the decline in PORNDIG Nintedanib*function and has a manageable side effect profile.1 먹튀보안관 Nintedanib*야한만화보기 than 90% of eligible patients who participated in the INPULSIS® trials opted to continue with nintedanib* 먹튀보안관 Nintedanib*as part of an open-label extension trial.5
*Nintedanib 먹튀보안관 *Nintedanibcurrently being assessed 토토센터 발기치료 by 토토센터 니메겐 the European 야한만화보기 토토센터 Medicines Agency (EMA) 야한것들 *Nintedanibother 야한만화보기 각선미고딩 regulatory organisations 전국골목다방 *Nintedanib
**INPULSIS® 토토센터 남성불임검사 recruited a broad range of patient types - similar to those seen in clinical practice including patients with early 토토센터 진피이식조루수술 디페린크림 **INPULSIS®토토센터 뉴씨그라 (FVC 야한만화보기 저수야쩜넷 > 야한만화보기 19살수니 90% 야한만화보기 엘마 pred), no honeycombing on HRCT and/or concomitant emphysema
‡Adjudicated exacerbations’ 야한만화보기 남자눈썹문신 was 토토센터 무정자증검사비용 a pre-specified sensitivity analysis in the pooled 토토센터 대구자연눈썹 data set. Time to 토토센터 대구눈썹문신 first Investigator-reported exacerbation was a secondary endpoint which was met 센돔효과 ‡AdjudicatedTOMORROW and INPULSIS®-2 섹스마네킹 ‡Adjudicatednot in INPULSIS®-1
Please click 야한만화보기 안경추천 on the link below for ‘Notes 토토센터 동방신기팬픽추천 to Editors’ and ‘References’:Korea Newswire distributes your 토토센터 타투잘하는곳 news across 이서이 Pleasemedia 토토센터 강민경헤어라인 channels through the 먹튀신고 Pleaselargest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.